{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:11:00Z","timestamp":1777349460754,"version":"3.51.4"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>As multiple myeloma (MM) therapies advance, understanding patients', caregivers', and physicians' perspectives on, and satisfaction with, available treatment options and their impact on quality of life (QoL), is important.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>EASEMENT is a real\u2010world, observational, cross\u2010sectional study conducted in 19 sites within the UK, Canada, and Italy using retrospective chart reviews and surveys. Enrolled patients had clinical history available since diagnosis and had received \u22651\u2009cycle of their current line of therapy. Primary objectives were to describe patient\/caregiver QoL (EQ\u20105D\u20105L questionnaire), patient preference for oral\/injectable therapies (single discrete\u2010choice question), and patient satisfaction (TSQM\u20109 questionnaire).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between October 2018 and March 2020, 399 patients were enrolled (<jats:italic>n<\/jats:italic>\u2009=\u2009192 newly diagnosed multiple myeloma [NDMM], <jats:italic>n<\/jats:italic>\u2009=\u2009206 relapsed\/refractory multiple myeloma [RRMM], <jats:italic>n<\/jats:italic>\u2009=\u20091 missing). Among NDMM and RRMM patients, 78%\/22% and 42%\/58% were receiving injectables\/orals, respectively. Both NDMM and RRMM patients significantly preferred orals versus injectables (<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.0001). No significant differences were reported in treatment satisfaction or QoL, but treatment convenience favoured orals over injectables with near significance (<jats:italic>p<\/jats:italic>\u2009=\u2009.053).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MM patients perceived greater convenience and preference for orals versus injectables. Oral treatments are useful for patients who cannot or prefer not to travel to clinics, or cannot perform self\u2010injection within the community.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.14180","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T08:16:20Z","timestamp":1708676180000},"page":"889-899","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The <scp>EASEMENT<\/scp> study: <scp>A<\/scp> multicentre, observational, cross\u2010sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable\u2010containing or fully oral therapies"],"prefix":"10.1111","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-6959","authenticated-orcid":false,"given":"Robert","family":"Ayto","sequence":"first","affiliation":[{"name":"Department of Haematology Queen Alexandra Hospital  Portsmouth UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3095-5313","authenticated-orcid":false,"given":"Ombretta","family":"Annibali","sequence":"additional","affiliation":[{"name":"Hematology, Stem Cell Transplantation Fondazione Policlinico Universitario Campus Bio Medico di Roma  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0877-3310","authenticated-orcid":false,"given":"Patricia","family":"Biedermann","sequence":"additional","affiliation":[{"name":"Medical Affairs, Europe &amp; Canada Takeda Pharmaceuticals International AG  Zurich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-9814","authenticated-orcid":false,"given":"Montserrat","family":"Roset","sequence":"additional","affiliation":[{"name":"Real World Solutions IQVIA  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9911-286X","authenticated-orcid":false,"given":"Emilio","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Real World Solutions IQVIA  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[{"name":"Medical Oncology &amp; Hematology CancerCare Manitoba  Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2128"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010055"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(10)70008-6"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-496"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/BLCTT.S327016"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01296-2"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.12703\/r\/11-28"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27973"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0002"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106629"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07018-6"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14236007"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00432-4"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S183187"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.10.1019"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-019-00184-9"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0724"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00543-y"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16357"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1963.03060120024016"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/9.3_Part_1.179"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1271657"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.019729"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.934.934"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.10.002"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2019.1634541"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1867469"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijh-2018-0014"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2019.100243"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27819"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T06:36:23Z","timestamp":1714113383000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/ejh.14180"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14180","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"2023-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}